NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

NAMS, USA

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

https://www.newamsterdampharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NAMS
stock
NAMS

What drives NAMS stock price - Institutional Holding Changes & Superior Capital Growth earlytimes.in

Read more →
NAMS
stock
NAMS

Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$46.6436

Analyst Picks

Strong Buy

5

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-9.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-9,428.45 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 97.07% of the total shares of NewAmsterdam Pharma Company N.V. Ordinary Shares

2.

FCPM III SERVICES BV

(9.44%)

since

2025/06/30

3.

RA Capital Management, LLC

(9.0021%)

since

2025/06/30

4.

American Funds SMALLCAP World A

(7.4547%)

since

2025/06/30

5.

Capital World Investors

(7.4473%)

since

2025/06/30

6.

Viking Global Investors LP

(6.1961%)

since

2025/06/30

7.

Deerfield Management Co

(4.5423%)

since

2025/06/30

8.

Wellington Management Company LLP

(2.9504%)

since

2025/06/30

9.

Adage Capital Partners Gp LLC

(2.6752%)

since

2025/06/30

10.

Jennison Associates LLC

(2.6158%)

since

2025/06/30

11.

Medicxi Ventures Management (Jersey) Ltd

(2.5478%)

since

2025/06/30

12.

Polar Capital Biotech S Inc

(2.4417%)

since

2025/07/31

13.

Polar Capital Holdings PLC

(2.2355%)

since

2025/06/30

14.

AllianceBernstein L.P.

(2.0702%)

since

2025/06/30

15.

Cormorant Asset Management, LLC

(1.9311%)

since

2025/06/30

16.

Vanguard Health Care Inv

(1.9146%)

since

2025/06/30

17.

Capital Research & Mgmt Co - Division 3

(1.8313%)

since

2025/06/30

18.

HHG PLC

(1.7421%)

since

2025/06/30

19.

FMR Inc

(1.691%)

since

2025/06/30

20.

Woodline Partners LP

(1.6845%)

since

2025/06/30

21.

Pictet Asset Manangement SA

(1.613%)

since

2025/06/30

22.

Maverick Capital Ltd

(1.3601%)

since

2025/06/30

23.

JPMorgan Chase & Co

(1.2953%)

since

2025/06/30

24.

Capital Group Global Equity Canada F

(1.1691%)

since

2025/06/30

25.

Pictet-Biotech P USD

(0.8665%)

since

2025/05/31

26.

JPMorgan Small Cap Growth A

(0.7343%)

since

2025/07/31

27.

Jennison Health Sciences Equity

(0.6901%)

since

2025/06/30

28.

PGIM Jennison Health Sciences Z

(0.6901%)

since

2025/07/31

29.

PGIM Jennison Small Company A

(0.6523%)

since

2025/07/31

30.

Jennison SMid Cap Core Equity

(0.6523%)

since

2025/06/30

31.

AB Small Cap Growth A

(0.6091%)

since

2025/07/31

32.

Pictet-Global Megatrend Sel I USD

(0.6058%)

since

2025/05/31

33.

Candriam Eqs L Biotech C USD Cap

(0.596%)

since

2025/07/31

34.

American Funds New Economy A

(0.5959%)

since

2025/06/30

35.

Capital Group New Economy Comp

(0.5959%)

since

2025/06/30

36.

Fidelity Select Biotechnology

(0.5693%)

since

2025/07/31

37.

BNP Paribas Health Cr Innovtr Cl Cap

(0.5296%)

since

2025/07/31

38.

AB Discovery Growth A

(0.4755%)

since

2025/07/31

39.

MEDICAL BioHealth EUR Acc

(0.4395%)

since

2025/06/30

40.

American Century U.S. Small Cap Growth

(0.4027%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.442

Latest Release

Date

2025-09-30

EPS Actual

-0.5314

EPS Estimate

-0.4033

EPS Difference

-0.1281

Surprise Percent

-31.763%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.